Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice

(2017) Vanessa Popp et al.   GASTROENTEROLOGY

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

(2017) Silvio Danese et al.   GUT

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

(2017) Nathaniel R West et al.   NATURE MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad

(2017) Bani Ahluwalia et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles

(2017) Friederike Fuchs et al.   Frontiers in Immunology

Innate Lymphoid Cells in Intestinal Inflammation

(2017) Alessandra Geremia et al.   Frontiers in Immunology

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial

(2016) Matthieu Allez et al.   GUT

Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition

(2016) Maria K. Magnusson et al.   Journal of Crohns & Colitis

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

(2016) Alon D. Levin et al.   Journal of Crohns & Colitis

Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells

(2016) David R Withers et al.   NATURE MEDICINE

Integrin-based therapeutics: biological basis, clinical use and new drugs

(2016) Klaus Ley et al.   NATURE REVIEWS DRUG DISCOVERY

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th9 cells in inflammatory bowel diseases

(2016) Benno Weigmann et al.   Seminars in Immunopathology

Role of regulatory T cell in the pathogenesis of inflammatory bowel disease

(2016) Akiko Yamada et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo

(2015) Anika Fischer et al.   GUT

Interleukin 10 (IL-10)-mediated Immunosuppression

(2015) Sharad K. Mittal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut

(2015) Andrea Michielan et al.   MEDIATORS OF INFLAMMATION

Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation

(2015) M K Magnusson et al.   Mucosal Immunology

Biologic agents for IBD: practical insights

(2015) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

The unusual suspects—innate lymphoid cells as novel therapeutic targets in IBD

(2015) Rimma Goldberg et al.   Nature Reviews Gastroenterology & Hepatology

Immunopathogenesis of IBD: current state of the art

(2015) Heitor S. P. de Souza et al.   Nature Reviews Gastroenterology & Hepatology

Optimizing the use of biological therapy in patients with inflammatory bowel disease

(2015) A. C. Moss   Gastroenterology Report

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

(2015) Man Cai Wang et al.   MEDICINE

The molecular regulation of Janus kinase (JAK) activation

(2014) Jeffrey J. Babon et al.   BIOCHEMICAL JOURNAL

Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

(2014) Nikolai V Kuznetsov et al.   BMC GASTROENTEROLOGY

IL-9 and its receptor are predominantly involved in the pathogenesis of UC

(2014) Nancy Nalleweg et al.   GUT

Future directions in inflammatory bowel disease management

(2014) Geert R. D'Haens et al.   Journal of Crohns & Colitis

Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes

(2014) J. Pene et al.   JOURNAL OF IMMUNOLOGY

TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

(2014) Katharina Gerlach et al.   NATURE IMMUNOLOGY

Immunopathology of inflammatory bowel disease

(2014) Kori L Wallace   WORLD JOURNAL OF GASTROENTEROLOGY

Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease

(2014) Xiao-Rong Xu   WORLD JOURNAL OF GASTROENTEROLOGY

Inflammatory Bowel Disease: The Classic Gastrointestinal Autoimmune Disease

(2014) Abha Kaistha et al.   Current Problems in Pediatric and Adolescent Health Care

Association of Levels of Antibodies from Patients with Inflammatory Bowel Disease with Extracellular Proteins of Food and Probiotic Bacteria

(2014) Arancha Hevia et al.   Biomed Research International

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

Innate and adaptive immunity in inflammatory bowel disease

(2013) Alessandra Geremia et al.   AUTOIMMUNITY REVIEWS

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

(2013) C. C. Mok et al.   CLINICAL RHEUMATOLOGY

Defective Antibacterial Barrier in Inflammatory Bowel Disease

(2013) Thomas Klag et al.   DIGESTIVE DISEASES

Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues

(2013) Jochem H Bernink et al.   NATURE IMMUNOLOGY

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease

(2012) F. Zorzi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease

(2012) Pierre Desreumaux et al.   GASTROENTEROLOGY

Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy

(2012) Daniel Kotlarz et al.   GASTROENTEROLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis

(2012) Christopher J. Moran et al.   INFLAMMATORY BOWEL DISEASES

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

Rapid and Sustained Remission of Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome Through Treatment With Anakinra and Corticosteroids

(2012) Normi Bruck et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Targeting IL-17 and TH17 cells in chronic inflammation

(2012) Pierre Miossec et al.   NATURE REVIEWS DRUG DISCOVERY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Mechanisms of Treg-Mediated T Cell Suppression

(2012) Angelika Schmidt et al.   Frontiers in Immunology

In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

(2011) Petra Roll et al.   ARTHRITIS AND RHEUMATISM

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

(2011) Carl A Anderson et al.   NATURE GENETICS

Differentiation of Effector CD4 T Cell Populations

(2010) Jinfang Zhu et al.   Annual Review of Immunology

Adverse effects of biologics used for treating IBD

(2010) Andreas Stallmach et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

IL-6: Regulator of Treg/Th17 balance

(2010) Akihiro Kimura et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells

(2010) Valérie Staudt et al.   IMMUNITY

Genetics of ulcerative colitis

(2010) Alexandra I. Thompson et al.   INFLAMMATORY BOWEL DISEASES

Importance of disrupted intestinal barrier in inflammatory bowel diseases

(2010) Saʼad Y. Salim et al.   INFLAMMATORY BOWEL DISEASES

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

Severe Ulcerative Colitis After Rituximab Therapy

(2010) D. S. Ardelean et al.   PEDIATRICS

Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells

(2009) I D Iliev et al.   GUT

Differential regulation of interleukin 17 and interferon   production in inflammatory bowel disease

(2009) L. Rovedatti et al.   GUT

Plasticity of CD4+ T Cell Lineage Differentiation

(2009) Liang Zhou et al.   IMMUNITY

Intestinal Effector T Cells in Health and Disease

(2009) Craig L. Maynard et al.   IMMUNITY

Late Developmental Plasticity in the T Helper 17 Lineage

(2009) Yun Kyung Lee et al.   IMMUNITY

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

(2009) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Foxp3+ Regulatory T Cells, Th17 Effector Cells, and Cytokine Environment in Inflammatory Bowel Disease

(2009) Nicola Eastaff-Leung et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Anakinra for Rheumatoid Arthritis: A Systematic Review

(2009) M. MERTENS et al.   JOURNAL OF RHEUMATOLOGY

Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region

(2009) Jeffrey C Barrett et al.   NATURE GENETICS

A Crohn's disease–associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1

(2009) Eiichiro Noguchi et al.   NATURE IMMUNOLOGY

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

CD4 T-cell differentiation and inflammatory bowel disease

(2009) Lauren A. Zenewicz et al.   TRENDS IN MOLECULAR MEDICINE

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression

(2008) Massimo C. Fantini et al.   GASTROENTEROLOGY

Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease

(2008) D. E. Fassi et al.   GUT

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

High-frequency Haplotypes in the X Chromosome Locus TLR8 Are Associated With Both CD and UC in Females

(2008) Masayuki Saruta et al.   INFLAMMATORY BOWEL DISEASES

Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation

(2008) Christopher R Weber et al.   LABORATORY INVESTIGATION

The role of IL-13 and NK T cells in experimental and human ulcerative colitis

(2008) I J Fuss et al.   Mucosal Immunology

Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset

(2008) Marc Veldhoen et al.   NATURE IMMUNOLOGY

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens

(2008) Yan Zheng et al.   NATURE MEDICINE